First Multikilogram Synthesis of the Next-Generation Oral Selective ERα Degrader Camizestrant-Reference-Cited by-同舟云学术

First Multikilogram Synthesis of the Next-Generation Oral Selective ERα Degrader Camizestrant

Published:2024-06-07 Issue:6 Volume:28 Page:2334-2342
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Tatton Matthew R.¹^ORCID,Currie Gordon S.¹,Adams Bradley¹,Aurell Carl-Johan²,Broberg Karl¹,Campbell Andrew D.³,Dai Kuangchu⁴,Malmgren Marcus²,Ikin Andrew¹,Janbon Sophie L. M.¹^ORCID,Sims Martin¹,Hemming-Taylor Joanna¹,Winterbottom Victoria¹

Affiliation:

1. Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Macclesfield SK10 2NA, United Kingdom

2. Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, SE 431 83 Gothenburg, Sweden

3. Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom

4. Changzhou SynTheAll Pharmaceutical Co. Ltd., Changzhou, Jiangsu 213127, P. R. China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00135

Reference16 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. An emerging generation of endocrine therapies in breast cancer: a clinical perspective

3. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

4. Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies

5. Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer